Daiichi Sankyo/Forest's Hypertension Therapy Azor Gets FDA Nod
This article was originally published in PharmAsia News
Executive Summary
Other combination products containing amlodipine include Novartis' Lotrel (amlodipine/benazepril) and Exforge (amlodipine/valsartan); the latter was just approved in June ("The Pink Sheet" DAILY, June 21, 2007).
|
<table width="100%"> <tbody> <tr> <td align="left"> </td> </tr> </tbody> </table><br /> <br /> <p> Other combination products containing amlodipine include Novartis' <strong><em>Lotrel</em></strong> (amlodipine/benazepril) and <strong><em>Exforge</em></strong> (amlodipine/valsartan); the latter was just approved in June (<a href='http://www.thepinksheetdaily.com/fdcreports/story/viewStory.do?targetAN=14070621006'>"The Pink Sheet" DAILY, June 21, 2007</a>). </p> <p> Under an agreement signed in August, Japan-based Daiichi and Forest agreed to co-promote the fixed-dose hypertensive. The two companies have co-promoted Benicar since 2001, though the agreement is slated to wind down at the end of March 2008 (<a href='http://www.thepinksheetdaily.com/fdcreports/story/viewStory.do?targetAN=14070821002'>"The Pink Sheet" DAILY, Aug. 21, 2007</a>). </p> <p> The August agreement called for Forest to pay Daiichi $20 million upfront plus other undisclosed payments. </p> <p> [An exclusive interview with Daiichi Sankyo U.S. CEO Joe Pieroni ran in "<em>The Pink Sheet" DAILY</em> in August (<a href='http://www.thepinksheetdaily.com/fdcreports/story/viewStory.do?targetAN=14070803003'>"The Pink Sheet" DAILY, Aug. 3, 2007</a>).] </p> <p> Daiichi submitted Azor in November 2006 (<a href='http://www.thepinksheetdaily.com/fdcreports/story/viewStory.do?targetAN=14061128006'>"The Pink Sheet" DAILY, Nov. 28, 2006</a>). </p> <p> <em>-Jonathan M. Block</em> (<a href='mailto:[email protected]'>[email protected]</a>) </p> <p> <em>This article is reprinted from "The Pink Sheet" DAILY, Sept. 27, 2007</em> </p> |